Transatlantic differences in assessment of risk of sudden cardiac death in patients with hypertrophic cardiomyopathy
Abstrakt
We have retrospectively evaluated 133 consecutive HCM patients (48.1 +- 15.8 years, 45% females) diagnosed in our center in whom all potential risk factors according to ACCF/AHA (Table 1) and ESC risk stratifications were available. Patients with ICD implanted in secondary prevention of SCD (Class I) have not been included.
Mean duration of follow-up was 5.5 +- 2.2 years (median 5.5 years; range 2-100 months, 677 patient-years). Nine patients (6.8%) underwent ICD implantation according to the National HCM Guidelines [4] during the study period.
Five patients (3.8%) died (two of pulmonary carcinoma, two of stroke and one soon after surgery). A total of three patients (2.3%) experienced one appropriate ICD discharge (the annual risk of sudden mortality event was 0.55%).
A comparison of risk stratification according to ESC and ACCF/AHA guidelines in these three patients is presented in Table 2.